Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Aug;46(7):904-912.
doi: 10.1097/MPA.0000000000000876.

Patterns of Care for Locally Advanced Pancreatic Adenocarcinoma Using the National Cancer Database

Arya Amini  1 , Bernard L Jones, Priscilla Stumpf, Stephen Leong, Christopher H Lieu, Colin Weekes, S Lindsey Davis, Wells A Messersmith, William T Purcell, Debashis Ghosh, Tracey Schefter, Karyn A Goodman
Affiliations

Patterns of Care for Locally Advanced Pancreatic Adenocarcinoma Using the National Cancer Database

Arya Amini et al. Pancreas. 2017 Aug.

Abstract

Objectives: The role of radiotherapy (RT) in locally advanced pancreatic cancer (LAPC) is uncertain. This study examines patterns of care and survival outcomes of LAPC undergoing chemotherapy alone versus chemotherapy plus RT (C + RT).

Methods: The National Cancer Database was queried for nonmetastatic LAPC patients who received chemotherapy alone or C + RT.

Results: Of the 13,695 patients included, 5306 underwent chemotherapy alone and 4971, C + RT. Use of C + RT declined from 2003 to 2011 (73%-53%), whereas chemotherapy alone increased. Of those receiving RT, rates of intensity-modulated radiotherapy (IMRT) increased (27%-72%), whereas 3-dimensional (3D) RT decreased (73%-28%). Unadjusted 1-year overall survival (OS) was longer for versus chemotherapy (45.6% vs 38.7%), as was 2-year OS (12.9% vs 11.9%) (hazard ratio, 0.88; 0.85-0.91; P < 0.001). Under multivariate analysis, C + RT was associated with improved OS (hazard ratio, 0.84; 0.81-0.87; P < 0.001). On subgroup analysis comparing C + IMRT, C + 3D RT, and chemotherapy alone, 1-year OS was 49.1%, 45.1%, and 38.7%, and 2-year OS was 13.1%, 11.6%, and 11.9% accordingly.

Conclusions: Utilization of RT in LAPC is decreasing, whereas chemotherapy alone is increasing. Of patients undergoing RT, rates of IMRT are increasing. Whereas C + IMRT appeared to be associated with improved OS compared with chemotherapy alone, 3D RT was not.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to report.

Figures

Figure 1.
Figure 1.
Percent rate of chemotherapy alone vs. chemotherapy + radiotherapy (RT) for locally advanced pancreatic cancer (LAPC) treated from 2003–2011 (A); percent rate of intensity-modulated radiotherapy (IMRT) and three-dimensional (3D) in subpopulation analysis of LAPC undergoing RT from 2003–2011 (B).
Figure 2.
Figure 2.
Unadjusted Kaplan Meier curves comparing overall survival outcomes between chemotherapy + radiotherapy (RT) and chemotherapy alone (A) and subpopulation analysis comparing chemotherapy + intensity modulated radiotherapy (IMRT), chemotherapy + three-dimensional (3D) RT and chemotherapy alone (B).
Figure 3.
Figure 3.
Kaplan Meier curves of overall survival adjusted by propensity score matching between chemotherapy + intensity modulated radiotherapy (IMRT) and chemotherapy alone (A), chemotherapy + three-dimensional (3D) RT and chemotherapy alone (B), and chemotherapy + IMRT and chemotherapy + 3D (C).
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65:5–29. - PubMed
    1. Huguet F, Girard N, Guerche CS, et al. Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. J Clin Oncol 2009;27:2269–2277. - PubMed
    1. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), Pancreatic Adenocarcinoma, Version 2 2015. http://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf Accessed November 2015.
    1. Loehrer PJ Sr., Feng Y, Cardenes H, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2011;29:4105–4112. - PMC - PubMed
    1. Goodman KA, Hajj C. Role of radiation therapy in the management of pancreatic cancer. J Surg Onc. 2013;107:86–96. - PubMed

MeSH terms